WO2007076933A1 - Interleukin-12p40 variants with improved stability - Google Patents
Interleukin-12p40 variants with improved stability Download PDFInfo
- Publication number
- WO2007076933A1 WO2007076933A1 PCT/EP2006/012301 EP2006012301W WO2007076933A1 WO 2007076933 A1 WO2007076933 A1 WO 2007076933A1 EP 2006012301 W EP2006012301 W EP 2006012301W WO 2007076933 A1 WO2007076933 A1 WO 2007076933A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variant
- amino acid
- protein
- substitutions
- variants
- Prior art date
Links
Classifications
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
- H04N21/435—Processing of additional data, e.g. decrypting of additional data, reconstructing software from modules extracted from the transport stream
- H04N21/4353—Processing of additional data, e.g. decrypting of additional data, reconstructing software from modules extracted from the transport stream involving decryption of additional data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/08—Payment architectures
- G06Q20/10—Payment architectures specially adapted for electronic funds transfer [EFT] systems; specially adapted for home banking systems
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0207—Discounts or incentives, e.g. coupons or rebates
- G06Q30/0215—Including financial accounts
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0207—Discounts or incentives, e.g. coupons or rebates
- G06Q30/0226—Incentive systems for frequent usage, e.g. frequent flyer miles programs or point systems
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/04—Billing or invoicing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
- G06Q40/12—Accounting
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L41/00—Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks
- H04L41/32—Specific management aspects for broadband networks
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L47/00—Traffic control in data switching networks
- H04L47/10—Flow control; Congestion control
- H04L47/24—Traffic characterised by specific attributes, e.g. priority or QoS
- H04L47/2491—Mapping quality of service [QoS] requirements between different networks
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/45—Management operations performed by the client for facilitating the reception of or the interaction with the content or administrating data related to the end-user or to the client device itself, e.g. learning user preferences for recommending movies, resolving scheduling conflicts
- H04N21/462—Content or additional data management, e.g. creating a master electronic program guide from data received from the Internet and a Head-end, controlling the complexity of a video stream by scaling the resolution or bit-rate based on the client capabilities
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/60—Network structure or processes for video distribution between server and client or between remote clients; Control signalling between clients, server and network components; Transmission of management data between server and client, e.g. sending from server to client commands for recording incoming content stream; Communication details between server and client
- H04N21/61—Network physical structure; Signal processing
- H04N21/6106—Network physical structure; Signal processing specially adapted to the downstream path of the transmission network
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/80—Generation or processing of content or additional data by content creator independently of the distribution process; Content per se
- H04N21/85—Assembly of content; Generation of multimedia applications
- H04N21/854—Content authoring
- H04N21/8549—Creating video summaries, e.g. movie trailer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L41/00—Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks
- H04L41/50—Network service management, e.g. ensuring proper service fulfilment according to agreements
- H04L41/5003—Managing SLA; Interaction between SLA and QoS
- H04L41/5019—Ensuring fulfilment of SLA
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Business, Economics & Management (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Accounting & Taxation (AREA)
- Finance (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Development Economics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Strategic Management (AREA)
- Signal Processing (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Theoretical Computer Science (AREA)
- General Business, Economics & Management (AREA)
- General Physics & Mathematics (AREA)
- Economics (AREA)
- Multimedia (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Marketing (AREA)
- Databases & Information Systems (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006332138A AU2006332138B2 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
PL06846989T PL1966238T3 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
SI200631366T SI1966238T1 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
AT06846989T ATE555125T1 (en) | 2005-12-30 | 2006-12-20 | INTERLEUKIN 12P40 VARIANTS WITH IMPROVED STABILITY |
EP20060846989 EP1966238B1 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
ES06846989T ES2384055T3 (en) | 2005-12-30 | 2006-12-20 | Variants of interleukin-12p40 with improved stability |
CA2635618A CA2635618C (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
DK06846989T DK1966238T3 (en) | 2005-12-30 | 2006-12-20 | INTERLEUKIN-12P40 variants with improved stability |
EA200870131A EA015338B1 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
CN2006800498186A CN101351475B (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
JP2008547880A JP5175214B2 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12P40 variant with improved stability |
BRPI0620648-4A BRPI0620648B1 (en) | 2005-12-30 | 2006-12-20 | IL-12 P40 VARIANT, IL-12, IL-23 AND FUSION PROTEINS, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
KR1020087018718A KR101343682B1 (en) | 2005-12-30 | 2008-07-29 | - interleukin-12p40 variants with improved stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75538205P | 2005-12-30 | 2005-12-30 | |
US60/755,382 | 2005-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007076933A1 true WO2007076933A1 (en) | 2007-07-12 |
Family
ID=38049414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/012301 WO2007076933A1 (en) | 2005-12-30 | 2006-12-20 | Interleukin-12p40 variants with improved stability |
Country Status (18)
Country | Link |
---|---|
US (3) | US7872107B2 (en) |
EP (1) | EP1966238B1 (en) |
JP (1) | JP5175214B2 (en) |
KR (1) | KR101343682B1 (en) |
CN (1) | CN101351475B (en) |
AT (1) | ATE555125T1 (en) |
AU (1) | AU2006332138B2 (en) |
BR (1) | BRPI0620648B1 (en) |
CA (1) | CA2635618C (en) |
CY (1) | CY1112884T1 (en) |
DK (1) | DK1966238T3 (en) |
EA (1) | EA015338B1 (en) |
ES (1) | ES2384055T3 (en) |
PL (1) | PL1966238T3 (en) |
PT (1) | PT1966238E (en) |
SI (1) | SI1966238T1 (en) |
WO (1) | WO2007076933A1 (en) |
ZA (1) | ZA200806611B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506394A (en) * | 2008-10-21 | 2012-03-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cancer treatment with radiation and immune cytokines |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
WO2023002952A1 (en) * | 2021-07-19 | 2023-01-26 | Chugai Seiyaku Kabushiki Kaisha | Protease-mediated target specific cytokine delivery using fusion polypeptide |
WO2023242769A1 (en) * | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
ES2269366T3 (en) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
BR0207854A (en) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (en) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
ES2381025T3 (en) | 2001-12-04 | 2012-05-22 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
CA2551915C (en) | 2003-12-30 | 2015-06-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Il-7 fusion proteins |
PT1699821E (en) * | 2003-12-31 | 2012-08-23 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
PT1966238E (en) | 2005-12-30 | 2012-07-31 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
US20100048482A1 (en) * | 2008-08-15 | 2010-02-25 | Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
DK2709651T3 (en) * | 2011-05-19 | 2018-01-08 | Univ Rush Medical Center | IL-12-P40 MONOMER, MONOCLONAL ANTIBODY AGAINST P40 HOMODIMER, AND A COMBINATION OF THE TWO FOR THE TREATMENT OF AUTO-IMMUNE DISEASE |
ES2703826T3 (en) * | 2014-02-19 | 2019-03-12 | Merck Patent Gmbh | Immunotherapy with IL-12 for cancer |
KR102469450B1 (en) | 2016-05-18 | 2022-11-22 | 모더나티엑스, 인크. | Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof |
CN106533815B (en) * | 2017-01-13 | 2019-10-29 | 邦彦技术股份有限公司 | Gateway control method and device based on capability characteristics |
CN108574635B (en) * | 2017-03-09 | 2021-06-22 | 华为技术有限公司 | Routing priority configuration method, device and controller |
CN108623691B (en) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG (immunoglobulin G) -like long-acting immune fusion protein and application thereof |
WO2018213731A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
EP3648786A4 (en) | 2017-07-03 | 2021-12-15 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
CN110264184B (en) * | 2019-06-28 | 2021-07-23 | Oppo(重庆)智能科技有限公司 | Payment control method and related product |
EP4277922A2 (en) * | 2021-01-12 | 2023-11-22 | Askgene Pharma, Inc. | Chimeric molecules comprising il-12 agonist polypeptide |
AU2022345103A1 (en) * | 2021-09-17 | 2024-03-28 | Bicara Therapeutics Inc. | Caix targeting il-12 fusion proteins and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0433827B1 (en) * | 1989-12-22 | 1998-03-04 | F. Hoffmann-La Roche Ag | Cytotoxic lymphocyte maturation factor |
WO1999029732A2 (en) * | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
WO2001018051A2 (en) * | 1999-09-09 | 2001-03-15 | Schering Corporation | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
WO2001040257A2 (en) * | 1999-12-02 | 2001-06-07 | Maxygen, Inc. | Modified il-12 subunits and nucleic acids encoding them |
JP2001161378A (en) * | 1999-10-01 | 2001-06-19 | Toray Ind Inc | Method for producing pure protein, interleukin 12, protein inhibiting activity of interleukin 12, medicine for treating immunological disease of mammal, and method for treating immunological disease |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US647717A (en) * | 1897-12-17 | 1900-04-17 | Guilford S Wood | Rotary engine. |
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US5679543A (en) * | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
ATE120761T1 (en) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET. |
EP0294703B1 (en) | 1987-06-10 | 1995-05-10 | Dana-Farber Cancer Institute, Inc. | Bifunctional antibody constructs and method for selectively destroying cell populations |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
PH26813A (en) | 1987-09-02 | 1992-11-05 | Ciba Geigy Ag | Conjugates of cytokines with immunoglobulins |
US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
DE3812605A1 (en) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | IMMUNEGULATIVE SUBSTANCES AND SUBSTANCE MIXTURES FOR ACTIVE INFLUENCING OF THE DISEASE PROCESS |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
CA2066612C (en) | 1989-09-20 | 1998-12-08 | Stephen D. Gillies | Method of producing fusion proteins |
US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
WO1991013166A1 (en) | 1990-03-02 | 1991-09-05 | Abbott Biotech, Inc. | Antibody constructs with enhanced binding affinity |
EP0541716A1 (en) | 1990-07-27 | 1993-05-19 | Repligen Corporation | Novel methods and compositions for treatment of angiogenic diseases |
EP0556328A4 (en) | 1990-11-09 | 1994-06-08 | Abbott Lab | Bridging antibody fusion constructs |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
AU9052891A (en) | 1990-12-05 | 1992-07-08 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
DE69227693T2 (en) | 1991-08-30 | 1999-07-22 | Hutchinson Fred Cancer Res | HYBRID CYTOKINE |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
IL105914A0 (en) * | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
DE4228839A1 (en) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Methods for the detection and determination of mediators |
US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
WO1994025609A1 (en) | 1993-04-28 | 1994-11-10 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
US5585098A (en) * | 1993-11-23 | 1996-12-17 | Ovimmune, Inc. | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants |
ATE207366T1 (en) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | IMMUNOCONJUGATES |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
US6148321A (en) * | 1995-05-05 | 2000-11-14 | Intel Corporation | Processor event recognition |
WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
AU1407997A (en) | 1995-12-01 | 1997-06-19 | Beth Israel Hospital | Il-12 p40 subunit fusion polypeptides and uses thereof |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
AU1952497A (en) | 1996-02-13 | 1997-09-02 | Regents Of The University Of California, The | Novel antibody-cytokine fusion protein, and methods of making and using the same |
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
JPH1187664A (en) * | 1997-04-28 | 1999-03-30 | Nippon Steel Corp | Semiconductor device and its production |
EP1724282B1 (en) * | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
NZ502375A (en) | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
PL343462A1 (en) * | 1998-04-15 | 2001-08-13 | Lexigen Pharm Corp | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
RU2217168C2 (en) * | 1998-04-17 | 2003-11-27 | Лексиген Фармасьютикэлс Корпорейшн | Enhancement of immune response mediated by proteins fused of antibody and cytokine by means of combined administration of prostaglandin inhibitor |
AU751823B2 (en) | 1998-05-14 | 2002-08-29 | Merck Patent Gmbh | Fused protein |
BR9913331A (en) * | 1998-08-25 | 2001-05-15 | Lexigen Pharm Corp | Expression and export of angiogenesis inhibitors as immunofusins |
US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
SK9432001A3 (en) * | 1999-01-07 | 2003-02-04 | Lexigen Pharm Corp | Expression and export of anti-obesity proteins as Fc fusion proteins |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
ATE369384T1 (en) * | 1999-05-19 | 2007-08-15 | Emd Lexigen Res Ct Corp | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS FC FUSION PROTEINS |
US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
BR0013231A (en) * | 1999-08-09 | 2002-07-23 | Lexigen Pharm Corp | Multiple cytokine-antibody complexes |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
ES2269366T3 (en) * | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
DE60129695T2 (en) * | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | INCREASING IMMUNE RESPONSES MEDIATED BY ANTIBODY CYTOKIN FUSION PROTEINS BY COMBINED TREATMENT WITH MEDICAMENTS FOR INCREASING IMMUNOCYTIC INJECTION |
AU2002241922B2 (en) | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
JP2004525621A (en) * | 2001-01-18 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Bifunctional fusion protein having glucocerebrosidase activity |
RU2363707C2 (en) * | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Artificial proteins with lowered adjuvanticity |
EP1998266A3 (en) * | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
BR0207854A (en) * | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
DE60239454D1 (en) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
ES2381025T3 (en) * | 2001-12-04 | 2012-05-22 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
JP4494977B2 (en) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its IL-2 fusion protein |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
CA2551915C (en) * | 2003-12-30 | 2015-06-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Il-7 fusion proteins |
PT1699821E (en) * | 2003-12-31 | 2012-08-23 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
WO2005070967A2 (en) * | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
RU2437893C2 (en) * | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Il-7 versions with low immunising capacity |
PT1966238E (en) | 2005-12-30 | 2012-07-31 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
-
2006
- 2006-12-20 PT PT06846989T patent/PT1966238E/en unknown
- 2006-12-20 ES ES06846989T patent/ES2384055T3/en active Active
- 2006-12-20 JP JP2008547880A patent/JP5175214B2/en active Active
- 2006-12-20 WO PCT/EP2006/012301 patent/WO2007076933A1/en active Application Filing
- 2006-12-20 CA CA2635618A patent/CA2635618C/en active Active
- 2006-12-20 PL PL06846989T patent/PL1966238T3/en unknown
- 2006-12-20 EA EA200870131A patent/EA015338B1/en not_active IP Right Cessation
- 2006-12-20 AT AT06846989T patent/ATE555125T1/en active
- 2006-12-20 AU AU2006332138A patent/AU2006332138B2/en active Active
- 2006-12-20 EP EP20060846989 patent/EP1966238B1/en active Active
- 2006-12-20 DK DK06846989T patent/DK1966238T3/en active
- 2006-12-20 SI SI200631366T patent/SI1966238T1/en unknown
- 2006-12-20 CN CN2006800498186A patent/CN101351475B/en active Active
- 2006-12-20 BR BRPI0620648-4A patent/BRPI0620648B1/en active IP Right Grant
- 2006-12-29 US US11/647,661 patent/US7872107B2/en active Active
-
2008
- 2008-07-29 ZA ZA200806611A patent/ZA200806611B/en unknown
- 2008-07-29 KR KR1020087018718A patent/KR101343682B1/en active IP Right Grant
-
2010
- 2010-12-07 US US12/961,733 patent/US8188248B2/en active Active
-
2012
- 2012-05-23 US US13/478,897 patent/US9029330B2/en active Active
- 2012-06-29 CY CY20121100582T patent/CY1112884T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0433827B1 (en) * | 1989-12-22 | 1998-03-04 | F. Hoffmann-La Roche Ag | Cytotoxic lymphocyte maturation factor |
WO1999029732A2 (en) * | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
WO2001018051A2 (en) * | 1999-09-09 | 2001-03-15 | Schering Corporation | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
JP2001161378A (en) * | 1999-10-01 | 2001-06-19 | Toray Ind Inc | Method for producing pure protein, interleukin 12, protein inhibiting activity of interleukin 12, medicine for treating immunological disease of mammal, and method for treating immunological disease |
WO2001040257A2 (en) * | 1999-12-02 | 2001-06-07 | Maxygen, Inc. | Modified il-12 subunits and nucleic acids encoding them |
Non-Patent Citations (12)
Title |
---|
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
ALTSCHUL ET AL., NUCLEIC ACIDS RESEARCH, vol. 25, no. 17, 1997, pages 3389 - 3402 |
DATABASE JPO Proteins [online] 27 August 2002 (2002-08-27), "Process for producing highly pure protein, interleukin 12, protein inhibiting interleukin-12 activity, remedies for mammalian immunopathy and method of treating immunopathy.", XP002435977, retrieved from EBI accession no. JPOP:BD507325 Database accession no. BD507325 * |
DATABASE UniProt [online] 1 June 2003 (2003-06-01), "Interleukin-12 subunit beta precursor (IL-12B) (IL-12 subunit p40) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40).", XP002435979, retrieved from EBI accession no. UNIPROT:Q865W9 Database accession no. Q865W9 * |
DATABASE UniProt [online] 1 November 1999 (1999-11-01), "Interleukin-12 subunit beta precursor (IL-12B) (IL-12 subunit p40) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40).", XP002435978, retrieved from EBI accession no. UNIPROT:Q9XSQ5 Database accession no. Q9XSQ5 * |
GEARING D P ET AL: "Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor [1]", CELL 1991 UNITED STATES, vol. 66, no. 1, 1991, pages 9 - 10, XP002435952, ISSN: 0092-8674 * |
KARLIN, ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 68 |
KARLIN, ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 77 |
ODBILEG R ET AL: "Cloning and sequence analysis of llama cytokines related to cell-mediated immunity", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, AMSTERDAM, NL, vol. 102, no. 1-2, November 2004 (2004-11-01), pages 93 - 102, XP004586000, ISSN: 0165-2427 * |
TRINCHIERI G ET AL: "NATURAL KILLER CELL STIMULATORY FACTOR (NKSF) OR INTERLEUKIN-12 IS A KEY REGULATOR OF IMMUNE RESPONSE AND INFLAMMATION", PROGRESS IN GROWTH FACTOR RESEARCH, PERGAMON PRESS, GB, vol. 4, no. 4, 1992, pages 355 - 368, XP000575698, ISSN: 0955-2235 * |
WOLF S F ET AL: "CLONING OF CDNA FOR NATURAL KILLER CELL STIMULATORY FACTOR, A HETERODIMERIC CYTOKINE WITH MULTIPLE BIOLOGIC EFFECTS ON T AND NATURAL KILLER CELLS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 146, no. 9, 1 May 1991 (1991-05-01), pages 3074 - 3081, XP000941940, ISSN: 0022-1767 * |
YOON C ET AL: "Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12", EMBO JOURNAL 17 JUL 2000 UNITED KINGDOM, vol. 19, no. 14, 17 July 2000 (2000-07-17), pages 3530 - 3541, XP002435951, ISSN: 0261-4189 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506394A (en) * | 2008-10-21 | 2012-03-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cancer treatment with radiation and immune cytokines |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
US11655277B2 (en) | 2018-10-03 | 2023-05-23 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
US11851466B2 (en) | 2019-10-03 | 2023-12-26 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
WO2023002952A1 (en) * | 2021-07-19 | 2023-01-26 | Chugai Seiyaku Kabushiki Kaisha | Protease-mediated target specific cytokine delivery using fusion polypeptide |
WO2023242769A1 (en) * | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US8188248B2 (en) | 2012-05-29 |
PT1966238E (en) | 2012-07-31 |
JP5175214B2 (en) | 2013-04-03 |
KR20080090483A (en) | 2008-10-08 |
AU2006332138B2 (en) | 2012-03-22 |
DK1966238T3 (en) | 2012-07-16 |
US7872107B2 (en) | 2011-01-18 |
JP2009521911A (en) | 2009-06-11 |
CA2635618A1 (en) | 2007-07-12 |
EA200870131A1 (en) | 2008-12-30 |
ZA200806611B (en) | 2009-12-30 |
US20110097792A1 (en) | 2011-04-28 |
BRPI0620648B1 (en) | 2022-12-20 |
US9029330B2 (en) | 2015-05-12 |
CA2635618C (en) | 2015-10-06 |
US20070154453A1 (en) | 2007-07-05 |
AU2006332138A1 (en) | 2007-07-12 |
CN101351475A (en) | 2009-01-21 |
CN101351475B (en) | 2013-05-15 |
SI1966238T1 (en) | 2012-08-31 |
ES2384055T3 (en) | 2012-06-28 |
CY1112884T1 (en) | 2016-04-13 |
EP1966238A1 (en) | 2008-09-10 |
PL1966238T3 (en) | 2012-09-28 |
KR101343682B1 (en) | 2013-12-20 |
EP1966238B1 (en) | 2012-04-25 |
US20130034518A1 (en) | 2013-02-07 |
BRPI0620648A8 (en) | 2019-01-15 |
EA015338B1 (en) | 2011-06-30 |
ATE555125T1 (en) | 2012-05-15 |
BRPI0620648A2 (en) | 2011-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8188248B2 (en) | Nucleic acids encoding interleukin-12P40 variants with improved stability | |
CN101072793B (en) | Il-7 variants with reduced immunogenicity | |
CN100522242C (en) | Artificial proteins with reduced immunogenicity | |
Han et al. | IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization | |
US11008374B2 (en) | Uses of IL-15 antagonists for the treatment of autoimmune and inflammatory diseases | |
CA2210491C (en) | Antagonists of interleukin-15 | |
EP2409991B1 (en) | Antibody constant region variant | |
RU2701301C2 (en) | METHOD FOR PURIFYING CONJUGATES BASED ON IL-15/IL-15Rα | |
EP2409990A1 (en) | Antibody constant region variant | |
CN102648002A (en) | IL-17 family cytokine compositions and uses | |
CN101128487A (en) | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY | |
ZA200602110B (en) | CD20-Binding polypeptide compositions | |
WO2007027805A2 (en) | Method for generating anti-variable region monoclonal antibodies | |
ES2253887T3 (en) | AGONIST ANTIBODIES OF THE G-CSF RECEIVER AND THE SAME METHOD. | |
JP7175983B2 (en) | Novel growth hormone receptor antagonist and its fusion protein | |
CN1827649A (en) | Fusion toxin protein and uses thereof | |
TW201714894A (en) | Immunoglobulin fusion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680049818.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006846989 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008408 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2635618 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008547880 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870131 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006332138 Country of ref document: AU Ref document number: 1020087018718 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006332138 Country of ref document: AU Date of ref document: 20061220 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006332138 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006846989 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0620648 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080627 |